Clinical study on bevacizumab combined with almonertinib in treatment of EGFR mutant stage Ⅳ non-small cell lung cancer
Objective To investigate the effect of Bevacizumab Injection combined with Almonertinib Mesilate Tablets in treatment of EGFR mutant stage Ⅳ non-small cell lung cancer.Methods Patients(94 cases)with EGFR mutant stage Ⅳ non-small cell lung cancer in Linfen Central Hospital from January 2021 to January 2023 were divided into control and treatment groups according to the random number table method,and each group had 47 cases.Patients in the control group were po administered with Almonertinib Mesilate Tablets,110 mg/time,once daily.Patients in the treatment group were iv administered with Bevacizumab Injection on the basis of the control group,15 mg/kg,infusion once every 3 weeks.Patients in two groups were treated for 12 weeks.The clinical efficacies,quality of life,and serum factor levels in two groups were compared.Results After treatment,the disease control rate of the treatment group was 82.98%,higher than 59.57%of the control group,with a statistically significant difference(P＜0.05).After treatment,KPS scores and SF-36 scores of two groups were significantly increased,while serum levels of PTX3 and CCL20 in two groups were significantly decreased(P＜0.05).And KPS score and SF-36 score of the treatment group were higher,but the serum levels of PTX3 and CCL20 in the treatment group were lower than those in the control group(P＜0.05).Conclusion Bevacizumab Injection combined with Almonertinib Mesilate Tablets in treatment of EGFR mutant stage Ⅳ non-small cell lung cancer can effectively improve the disease control effect,significantly improve quality of life,and regulate serum levels of PTX3 and CCL20.
NETL
NSTL
万方数据
